Jonathan Lieber | U.S. CFO, Entera |
Adam Gridley | CEO |
Phillip Schwartz | President of R&D |
Arthur Santora | Chief Medical Officer |
Good morning and welcome to Entera Bio’s Conference Call to discuss the Interim Biomarker Data from the Phase 2 clinical trial of EB613 and the Financial and Operative Results from the First Quarter of 2020. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the call over to Jon Lieber, the U.S. based CFO of Entera.